Tien Hoang

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko et al. · Journal of Thoracic Oncology · 2020 · 587 citations · Full text

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

Makoto Nishio, Fabrice Barlési, Howard West et al. · Journal of Thoracic Oncology · 2020 · 430 citations · Full text

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

Daniel V.T. Catenacci, Niall C. Tebbutt, André M. Murad et al. · The Lancet Oncology · 2017 · 338 citations · Full text

Advanced Met-positive Gastric, First-line Therapy, Gastrointestinal Oncology +7

Clinical Model to Predict Survival in Chemonaive Patients With Advanced Non–Small-Cell Lung Cancer Treated With Third-Generation Chemotherapy Regimens Based on Eastern Cooperative Oncology Group Data

Tien Hoang, Ronghui Xu, Joan H. Schiller et al. · Journal of Clinical Oncology · 2004 · 263 citations · Full text

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko et al. · Journal of Clinical Oncology · 2018 · 220 citations

Cancer Management, Primary Pfs, Pharmacotherapy +16